SARS-CoV-2 Coronavirus (COVID-19) Update

May 27, 2020


At Genedata, safeguarding the health and safety of our employees and our customers is paramount. Ensuring business continuity for our customers is also crucially important. In response to the developing coronavirus situation, Genedata has implemented measures to ensure that our obligations to our employees and customers are met. This approach is under continual review and will be adapted as the situation evolves.

The following actions have been taken to ensure the health of all in the broader Genedata environment, and to enable the continued smooth running of our business operations.

  • All Genedata offices throughout the world continue to serve our customers as usual.

  • Genedata employees globally are working from home remotely as far as possible, with full connectivity to Genedata systems and customers, and to each other. All contact details remain unchanged.

  • All Genedata staff have been educated on appropriate hygiene and risk avoidance measures and have been instructed to self-isolate and seek medical advice if they feel unwell or develop flu-like symptoms such as elevated temperature or coughing.

  • Genedata staff who have visited (whether for business or personal reasons) any of the regions around specified major centers of infection in recent days are required to self-isolate at home for at least 14 days, without exception.

  • All business travel for Genedata staff has been cancelled.

  • Wherever possible, meetings have been replaced with virtual (web) meetings.

  • The Genedata Biopharma Partner Symposium scheduled for April 2–3 in Basel has been postponed and will take place in 2021. We look forward to welcoming delegates at that time, and thank them for their patience and understanding.

We remain fully contactable. If you have any queries or concerns about Genedata services, please contact us via any of the established channels.